News
Recent news about Panacea Venture and select portfolio companies
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
January 15, 2026
Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
January 15, 2026
Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
December 10, 2025
Chime Biologics Announces Strategic Collaboration with Beijing Libang Pharmaceutical on Global Blinatumomab Biosimilar Program
December 10, 2025
Chime Biologics Announces Strategic Collaboration with Beijing Libang Pharmaceutical on Global Blinatumomab Biosimilar Program
December 9, 2025
Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan
December 9, 2025
Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan
November 11, 2025
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
November 11, 2025
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.